Your session is about to expire
← Back to Search
Unknown
PLN-74809 for Sclerosing Cholangitis
Phase 2
Waitlist Available
Research Sponsored by Pliant Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Established clinical diagnosis of large duct PSC based on an abnormal cholangiography as assessed by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), and/or percutaneous transhepatic cholangiopancreatography (PTC) in the context of cholestatic liver chemistry
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-48 weeks
Awards & highlights
Study Summary
This trial is studying a potential new treatment for primary sclerosing cholangitis and liver fibrosis. It is assessing the safety and tolerability of the drug as well as how it is processed by the body.
Who is the study for?
This trial is for people with a condition called primary sclerosing cholangitis (PSC), which affects the liver's bile ducts. Participants should have abnormal liver tests or suspected liver fibrosis, but not advanced cirrhosis. They can be on stable IBD treatment and must not have other causes of liver disease like autoimmune hepatitis or viral infections.Check my eligibility
What is being tested?
The study is testing PLN-74809, a potential new medication for PSC, against a placebo (a substance with no active drug). It's designed to see how safe it is and how the body processes it. People will be randomly assigned to receive either PLN-74809 or placebo without knowing which one they're getting.See study design
What are the potential side effects?
While specific side effects are not listed here, common ones in trials like this may include gastrointestinal symptoms, headaches, fatigue, and possible allergic reactions. The safety profile of PLN-74809 will be closely monitored throughout the study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with large duct PSC based on specific liver tests.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12-48 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-48 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of participants with treatment-related adverse events and laboratory abnormalities, as assessed by CTCAE v5.0
Secondary outcome measures
Assessment of PLN-74809 plasma concentrations
Other outcome measures
Changes from Baseline to Week 12 in liver fibrosis biomarkers and alkaline phosphatase (ALP) levels
Trial Design
5Treatment groups
Experimental Treatment
Placebo Group
Group I: PLN-74809 Dose Level 4Experimental Treatment1 Intervention
Dose: 320 mg; PLN-74809 Dose Level 4 following PLN-74809 Dose Level 3
Group II: PLN-74809 Dose Level 3Experimental Treatment1 Intervention
Dose: 160 mg; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 2
Group III: PLN-74809 Dose Level 2Experimental Treatment1 Intervention
Dose: 80 mg; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1
Group IV: PLN-74809 Dose Level 1Experimental Treatment1 Intervention
Dose: 40 mg;
Group V: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PLN-74809
2020
Completed Phase 2
~260
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Primary Sclerosing Cholangitis (PSC) include ursodeoxycholic acid (UDCA), glucocorticoids, thiopurines, and vancomycin. UDCA works by reducing bile acid toxicity and improving bile flow, which can help alleviate cholestasis and liver inflammation.
Glucocorticoids and thiopurines are immunosuppressive agents that reduce inflammation and immune-mediated damage to the bile ducts. Vancomycin, an antibiotic, has shown some promise in small studies, potentially by altering gut microbiota and reducing bacterial translocation that may contribute to PSC.
These treatments are crucial for PSC patients as they aim to manage symptoms, slow disease progression, and improve quality of life. While the specific mechanism of PLN-74809 is not detailed, it is likely being investigated for its potential to target similar pathways involved in fibrosis and inflammation, which are central to PSC pathology.
New Therapeutic Targets in Autoimmune Cholangiopathies.β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis.
New Therapeutic Targets in Autoimmune Cholangiopathies.β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis.
Find a Location
Who is running the clinical trial?
Pliant Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
612 Total Patients Enrolled
Pliant Therapeutics Medical MonitorStudy DirectorPliant Therapeutics, Inc.
4 Previous Clinical Trials
566 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have liver cirrhosis confirmed by tests or symptoms like jaundice or swelling.I do not have liver disease from viruses, alcohol, or other causes.My PSC affects only small bile ducts, with no large duct issues confirmed by tests.I have suspected liver fibrosis confirmed by a specific liver test or biopsy.I am on a stable treatment for IBD and it will not change during the study.I have been on a stable dose of UDCA, less than 25 mg/kg/day, for over 3 months.I have been diagnosed with or suspected to have autoimmune hepatitis.I have been diagnosed with large duct PSC based on specific liver tests.
Research Study Groups:
This trial has the following groups:- Group 1: PLN-74809 Dose Level 1
- Group 2: PLN-74809 Dose Level 3
- Group 3: Placebo
- Group 4: PLN-74809 Dose Level 4
- Group 5: PLN-74809 Dose Level 2
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger